Estrogen Receptor Binding to DNA Is Not Required for Its Activity through the Nonclassical AP1 Pathway*

Received for publication, September 13, 2000, and in revised form, December 20, 2000
Published, JBC Papers in Press, January 18, 2001, DOI 10.1074/jbc.M008384200

Monika Jakacka, Masafumi Ito, Jeffrey Weiss, Pei-Yu Chien, Barry D. Gehm, and J. Larry Jameson‡

From the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Medical School, Chicago, Illinois 60611

In the classical signaling pathway, the estrogen receptor (ER) binds directly to estrogen response elements (ERE) to regulate gene transcription. To test the hypothesis that the nonclassical pathway involves ER interactions with other proteins rather than direct binding to DNA, mutations were introduced into the DNA binding domain (DBD) of the mouse ERα. The effects of these DBD mutations were examined in DNA binding assays using reporter constructs containing either EREs (classical) or AP1 (nonclassical) response elements. Using the AP1 reporter, there was a reversal of ER action relative to that seen with the ERE reporter. Estradiol induced suppression, and the antiestrogen ICI 182,780 stimulated transcription of the AP1 reporter. DBD mutations in the proximal (P-box) of the first zinc finger of the ER (E207A/G208A and E207G/G208S) eliminated ERE binding. These mutants were inactive using the ERE reporter but retained partial or full activity with the AP1 reporter. The DBD mutant ERs interacted with Jun when tested in mammalian cell two-hybrid assays. Two mutations (K366D and I362R) in the ER ligand binding domain known to alter coactivator interactions impaired transcriptional responses using either the ERE or AP1 reporters. We concluded that ER action through the AP1 response element involves interactions with other promoter-bound proteins instead of, or in addition to, direct binding to DNA. Interactions with coactivators were required for both pathways. These data supported a model in which ER-mediated transcriptional activation or repression is dependent on the ligand and the nature of the response element in the target gene.

Estrogen has a wide range of physiologic activities, including the control of development, reproduction, and metabolism as well as effects on cell growth and differentiation. Most, if not all, actions of estrogen occur through its receptors, ERα and ERβ. The functional domains of the ER are relatively well defined. These domains include the N-terminal domain (A/B regions), DNA binding domain (C), hinge (D), ligand binding domain (E), and the C-terminal domain (F). A ligand-dependent activation function 2 in the C-terminal region of the ligand binding domain (LBD) and a ligand-independent activation function 1 in the N-terminal domain have also been characterized (1, 2).

In the traditional model of ER action, the receptor binds as homodimers (3) or heterodimers (4–7) to estrogen response elements (ERE)s in the promoters of many, though not all, estrogen-responsive genes. Similar to other nuclear receptors, the ER recruits an array of transcriptional cofactors (coactivators and corepressors) that bind to the receptor and also interact with other transcription factors, including components of the general transcription factor apparatus. Some of the cofactors also possess chromatin-remodeling activities or recruit additional proteins to the complex to mediate transcription (reviewed in Ref. 8).

It is now recognized that the type of ligand bound to the ER influences its interaction with cofactors. The crystal structures of the ER LBD when bound to an agonist (estradiol) or an antagonist (raloxifene) have been solved. Comparison of these structures suggests a molecular basis for the differential ligand-dependent cofactor binding (9). The binding of 17β-estradiol induces a major shift in the position of helix 12, one of several helices that form the coactivator interaction surface. Substitution of raloxifene or 4-hydroxytamoxifen (10) for estradiol changes the orientation of helix 12 in a manner that partially obscures the residues involved in the coactivator interaction. Antagonist-bound ER binds to corepressors in vitro (11, 12), but these interactions are not as strong as those seen with certain other nuclear receptors such as the thyroid hormone or retinoic acid receptors. The region of cofactor binding has been localized to a hydrophobic surface of the LBD.

Not all genes that are regulated by the ER contain an ERE. The mechanism for estrogen action through this “nonclassical” pathway (or pathways) is not clear. However, several lines of evidence suggest that the ER interacts with other transcription factors bound to their response elements (e.g. NF-κB, SP1, electrophile response element, AP1) in these target genes. Repression exerted through the NF-κB site has been examined in the context of the human interleukin 6 promoter (13, 14). In this case, repression is dependent on two transcription factors, NF-κB and CAAT enhancer-binding protein β. A direct interaction of NF-κB and ER has been demonstrated and requires the DBD and the D region of ER (13). This direct protein binding contributes to interleukin 6 promoter repression by estrogen (14).

The ER has also been shown to affect gene expression from promoters containing an AP1 site. In some cases, such as the
collagenase (15–17), human insulin growth factor 1 (18), or chicken ovalbumin (19) promoters, estrogen activates expression. Of interest, in the context of the collagenase promoter ER antagonists also stimulate expression (15, 17). Other genes containing an AP1 site in their promoters are negatively regulated by estrogen, including the ovine follicle-stimulating hormone β (20) and human choline acetyltransferase gene (21).

In this report, we further examine the mechanism by which the ER acts through the nonclassical pathway, using the AP1 response element as a model. We demonstrate, using selective DBD mutations, that DNA binding by the ER is not necessary for its activity through this nonclassical pathway.

**EXPERIMENTAL PROCEDURES**

**Plasmids**—The mouse ERα expression vector was provided by Malcolm Parker (Imperial Cancer Research Fund, London, United Kingdom) and subcloned into pcDNA3.1(−/−) (Invitrogen). Point mutations were introduced using overlapping polymerase chain reactions, and the sequence of the mutated cDNA was confirmed by DNA sequencing. The Gal4-Jun expression vector contains the Gal4 DNA binding domain fused to a fragment of human c-Jun lacking its DNA binding domain (amino acid 332 to the C terminus) in pSG424 (22). The Gal4 DNA binding domain was also used as a control. The reporter plasmid ERE-tk109-luc has been described previously (23). The AP1-luc reporter contains seven AP1 sites linked to a basal promoter (Stratagene); the 73col-luc reporter contains a fragment of collagenase promoter (−73 to +63) containing one AP1 site (24). The UAS-E1b-TATA-luc reporter contains five copies of the upstream activating sequence (UAS) upstream of E1b-TATA in the pA5-luc vector (25).

**Cell Culture**—TSA-201 cells, derived from estrogen receptor negative human embryonic kidney 293 cells (26), were cultured in Dulbecco’s modified Eagle’s medium supplemented with 5% fetal bovine serum. MCF-7 cells (estrogen receptor positive, subclone W88, derived from human breast adenocarcinoma, provided by V. Craig Jordan (Northwestern University Medical School, Chicago, IL), were cultured in minimum Eagle’s medium supplemented with nonessential amino acids, 10 mM Hepes, and 5% calf serum. Four days before transfection, cells were harvested using phenol red-free trypsin-EDTA and cultured in estrogen-depleted media (prepared without phenol red and supplemented with sera extracted three times with dextran-coated charcoal).

**Transfections and Luciferase Assays**—Cells were transfected to 12- or 24-well plates in estrogen-depleted medium 1 day prior to transfection. Cells were transfected with calcium phosphate precipitates as previously described (27), and MCF-7 cells were transfected with liposomes as previously described (23). ERE, AP1, and 73col luciferase reporter plasmids (500 ng/well) were transfected together with 10 ng/well receptor expression vector or empty vector used as a control. Mammalian cell two-hybrid experiments used the UAS-E1b-TATA-luc reporter (500 ng/well) to detect Gal4-Jun (50 ng/well) activity and its interaction with various ER mutants (1 ng/well). 17β-Estradiol was purchased from Sigma and IC50 182,780 was provided by Alan Wakeling (Zeneca Pharmaceuticals). Estradiol (1 nm) and ICI 182,780 (100 nm) were added to treatment media as stock solutions in absolute ethanol. Ethanol was added to control media in the same final solvent concentration (typically 0.1%). Luciferase activity was determined 24 or 48 h after transfection by using an AutoLumat LB953 luminometer (EG&G) and expressed as relative light units. The mean and standard errors of triplicate or quadruplicate samples are shown for representative experiments. All transfection experiments were repeated three or more times with similar results.

**Electrophoretic Mobility Shift Assays**—The ER probe and the conditions for electrophoretic mobility shift assays were previously described (28). Protein samples were prepared by in vitro translation (TNT, T7 coupled in vitro translation kit, Promega), preincubated with a binding buffer containing 10 mM Hepes, pH 7.9, 50 mM KCl, 5% glycerol, 50 μg/ml herring testes DNA, and 1 mM 17β-estradiol at 4 °C for 30 min, and then incubated with labeled ERE probe at 4 °C for 30 min in a total volume of 20 μl. The samples were loaded and subjected to electrophoresis through 4% nondenaturing polyacrylamide gels, and radiolabeled bands were visualized by autoradiography.

**Western Blots**—TSA-201 cells were transfected with the indicated expression vectors and cultured in medium supplemented with regular (unextracted) serum. Nuclear extracts were prepared as described elsewhere (29). The extracts were fractionated using 10% SDS-polyacrylamide gel electrophoresis gels and transferred onto Hybond ECL transfer membranes (Amersham Pharmacia Biotech). Immunodetection was performed using mouse monoclonal ER antibody D-12 (Santa Cruz Biotechnology) and anti-mouse, horseradish peroxidase-conjugated IgG (Promega). Proteins were visualized using an ECL Plus kit (Amersham Pharmacia Biotech) according to the manufacturer’s instructions.

**RESULTS**

**ER Agonists Repress and Antagonists Stimulate Transcription Mediated by the Nonclassical API Pathway**—The response to ER agonists and antagonists was examined using classical and nonclassical pathway reporter constructs. For the classical pathway, ERE-tk109-luc, which contains two copies of the vitellogenin gene ERE upstream of the 109-base pair fragment of thymidine kinase promoter, was used. For the nonclassical pathway, two different AP1 luciferase reporters were used: 73col-luc, which contains a fragment of the collagenase promoter (−73 to +63) and includes a single AP1 site (24), and AP1-luc, which contains seven AP1 sites upstream of a basal promoter (Stratagene). Transfections were performed in ER-negative TSA-201 cells.

In the absence of transfected ER, hormone treatments did not alter the activity of any of these reporter constructs, confirming the absence of endogenous ER or other estrogen-responsive pathways (data not shown). When ER was cotransfected with the ERE reporter, estradiol activated and the antiestrogen ICI 182,780 repressed transcription (Fig. 1, TSA, ERE reporter). The responses to agonists and antagonists were reversed when the AP1-luc reporter was used. Estradiol suppressed transcription, and the antiestrogen ICI 182,780 stimulated promoter activity (Fig. 1, TSA, AP1 reporter). These effects were specific for the presence of AP1 sites; no response was observed using a reporter lacking the AP1 sites but retaining the remainder of the promoter and the vector backbone (data not shown). A reporter containing a fragment of the native collagenase promoter (−73 to +63), which contains a single AP1 site, displayed a response pattern similar to the artificial AP1-luc reporter (Fig. 1, TSA, 73col reporter), and all subsequent experiments were performed with AP1-luc. Consistent with the effects of estradiol and ICI 182,780, diethylstilbestrol repressed whereas raloxifene, tamoxifen, and 4-hydroxysteramoxifen stimulated AP1-luc transcription (data not shown).

Reporter constructs were also transfected into ER-positive MCF-7 cells in the absence of the ER expression vector. Responses mirrored those observed in TSA cells. Estradiol activated the ERE reporter and repressed the AP1-luc and 73col-luc reporters, whereas ICI 182,780 repressed the ERE reporter and activated the AP1-luc and 73col-luc reporters (Fig. 1, MCF-7). The ligand effects on the nonclassical pathway were enhanced when exogenous ER was transfected into MCF-7 cells along with the AP1-luc reporter (data not shown).

**Mutations That Abolish ER Binding to the ERE Do Not Disrupt Activity through the Nonclassical API Pathway**—To determine whether the nonclassical pathway requires ER binding to DNA, four mutations were introduced into the ER DBD. The mutant receptors were examined for DNA binding and functional activity using the ERE and AP1 reporters. These mutations were hypothesized to preclude ER action through the classical pathway but to retain the ability to interact with other transcription factors, thereby potentially mediating actions through the nonclassical pathway. The structure of the zinc fingers and the location of introduced mutations are depicted in Fig. 2A. The first three mutants are all within the “P-box” of the first zinc finger, a region known to mediate interaction with DNA (30). The E207G/G208S mutant (a double mutant) has been demonstrated previously to disrupt binding to the ERE (31). The E207A/G208A mutant was created with the intent of better preserving the protein structure by
substituting with alanine residues. In the third mutant, Lys-210 was changed to Ala, disrupting the direct interaction of the positively charged lysine with DNA (32). The fourth mutant, A277T, is in the “D-box” of the second zinc finger, a region that has been implicated in homodimerization and thereby DNA binding (32).

The DNA binding properties of these mutants were tested in gel mobility shift assays (Fig. 2B). E207G/G208S had no detectable binding and E207A/G208A exhibited minimal residual binding (0.8%) relative to the wild type (WT) ER. The mutation in the dimerization domain (A227T) retained a small amount of ERE binding (2.4% WT). The K210A mutation was substantially less effective than the other mutants at disrupting DNA binding (8.1% WT).

The ability of these mutants to act through the classical and nonclassical pathways was examined in transient transfection assays (Fig. 3, A and B). Three of the mutants (E207G/G208S, E207A/G208A, K210A) showed little or no estrogen responsiveness through the ERE-mediated classical pathway (Fig. 3A). The A227T D-box mutant retained significant estrogen responsiveness through the ERE reporter. The loss of activity with the E207G/G208S and E207A/G208A mutants was confirmed using artificial reporters containing EREs from other estrogen responsive genes such as human pS2 and human oxytocin (data not shown). Western blot analysis of nuclear extracts demonstrated equal expression of the WT and mutant proteins (Fig. 3C).

In the AP1 reporter assay (Fig. 3B), the E207G/G208S, E207A/G208A, and A227T mutants each retained the nonclassical pattern of response. The E207A/G208A mutant was the most active, with responses similar to those of the WT ER. Thus, E207A/G208A exhibits selective loss of ERE binding and transcriptional control by the classical pathway but retains full regulation by the nonclassical pathway. The K210A mutant lost the ability to act through the nonclassical pathway.

Functional Interaction Between ER and the AP1 Protein Jun—A mammalian two-hybrid assay was used to test the hypothesis that ER interacts with AP1 proteins in the nonclassical pathway. WT or mutant ER was cotransfected with a Gal4-Jun fusion protein, using UAS-E1b-TATA-luc as a reporter (Fig. 4B). In control experiments, the Gal4 DBD alone did not activate the UAS-E1b-TATA-luc reporter, either in the absence or presence of ER. Gal4-Jun increased basal expression but did not confer responsiveness to estradiol or ICI 182,780. When WT ER was coexpressed, estradiol repressed Gal4-Jun-mediated transcription, whereas ICI 182,780 activated transcription, a pattern that mimics the activity seen in the AP1 reporter assays.

The activities of the DBD mutants were also tested in this assay. E207A/G208A, a mutant that preserved the nonclassical response pattern for AP1 (Fig. 3B), strongly activated Gal4-Jun-mediated transcription in the presence of ICI 182,780 (Fig. 4C). The E207G/G208S and A227T mutants, which exhibited
less robust activity in the AP1 reporter assay (Fig. 3B), activated Gal4-Jun to a lesser extent than E207A/G208A or WT ER (Fig. 4C). K210A lost all activity in both the AP1 reporter assay and in the interaction assay. Thus, the transcriptional properties of the ER DBD mutants are similar in the Gal4-Jun and AP1 reporter assays.

**ER Mutations That Abolish Interactions with Coactivators Disrupt Signaling through the Classical and Nonclassical Pathways**—The LBD of ER plays an important role in cofactor interactions, which are central to ER activity through the ERE. Two different point mutations (I362R and K366D) were introduced into ER helix 3, which together with helices 4, 5, and 12 forms a hydrophobic cavity that is involved in cofactor interactions. The specific substitutions were chosen based on their high degree of conservation when compared with related nuclear receptors (Fig. 5A) and because similar mutations have been reported to disrupt interactions with specific coactivators, including steroid receptor coactivator 1 (SRC-1) (33, 34). Using a mammalian two-hybrid system, these mutant ERs were confirmed to lose most (I362R) or all (K366D) of their interaction with Gal4-SRC-1 and Gal4-GRIP-1 in the presence of estradiol (data not shown).

The K366D mutation largely eliminated the effects of estradiol and ICI 182,780 (Fig. 5, B and C). With the ER reporter, basal activity was greatly reduced, as were estradiol activation and ICI suppression. With the AP1 reporter, estradiol suppression was eliminated and ICI stimulation was markedly decreased. The effect of the I362R mutation was more dependent on the ligand (estradiol versus ICI). Estradiol stimulation of the ERE reporter and suppression of the AP1 reporter was retained. ICI 182,780 stimulated the ERE reporter and elicited a small decrease with the AP1 reporter. These results indicate that ER mutations that alter binding to transcriptional cofactors impair ER action through both the classical and nonclassical pathways.
The effects of the helix 3 mutants in the mammalian two-hybrid assays with Gal4-Jun (Fig. 5D) were similar to those seen with the AP1 reporter, consistent with the idea that ER actions on the AP1 reporter are mediated through interactions with Jun.

DISCUSSION

In the classical pathway, ER action is mediated by direct receptor binding to EREs. Agonist binding induces an ER conformation that favors interactions with coactivators and general transcription factors, resulting in increased transcription. When bound to an antagonist, the ER does not interact with coactivators and, in turn, does not activate transcription. In contrast, the mechanism by which ER regulates nonclassical pathways is less well established. We hypothesized that this mechanism involves ER interactions with other proteins, rather than direct binding to DNA. AP1-regulated genes were
used as a model system for the nonclassical pathway. With these reporter genes, agonists repress and antagonists activate transcription in the presence of ER. We identified a DBD mutant of ER (E207A/G208A) that lost transactivation through the classical pathway but retained regulation of the nonclassical pathway. These data provide new insights into mechanisms by which nonclassical ER signaling occurs. First, ligands traditionally considered estrogen receptor agonists or antagonists have an opposite effect on the nonclassical API1 pathway, where agonists repress and antagonists activate transcription. Such a reversal of activity suggests that a novel mechanism mediates ER activity through the nonclassical API1 pathway. Second, it is possible to abolish the ability of ER to bind to an ERE and still preserve activity through the nonclassical pathway. However, as discussed below, the ER DBD likely interacts with other proteins, such as Jun, and this interaction requires a structurally intact DBD. Third, the interaction between ER and cofactors has functional significance both in the classical and the nonclassical pathways.

In the nonclassical pathway, we found that estradiol represses and ICI 182,780 activates transcription via the API1 reporter, a pattern that is the opposite of the ligands’ effects on the ERE reporter. Though the activation of transcription by an antagonist is consistent with other reports (15–17), the repressive effect of estradiol on the collagenase promoter has not been observed previously, perhaps because of differences in experimental conditions. However, estrogen-mediated suppression of gene expression is a common physiologic phenomenon and includes genes such as interleukin 6 (13, 14), tumor necrosis factor α (35), follicle-stimulating hormone β (20), choline acetyltransferase (21), quinone reductase (36), and lipoprotein lipase (37). In many cases, negative regulation involves the API1 site (20, 21, 37).

ER action through the nonclassical pathway does not involve ER binding to DNA and appears to be mediated by protein-protein interactions. For example, the P-box mutation E207A/G208A in the first zinc finger eliminates DNA binding and ERE activation but preserves activity through the nonclassical pathway. A possible candidate for the protein-protein interaction in the nonclassical pathway is Jun, a member of the API1 protein family. This idea is supported by evidence for ER interaction with Gal4-Jun in mammalian two-hybrid assays and by the observation that ER mutants have similar effects when tested in Gal4-Jun interaction assays or in API1 reporter assays. The ICI-induced interaction between Jun and ER detected in a two-hybrid assay may not be direct, as other cellular proteins (e.g., coactivators) may participate in the Gal4-Jun-ER interaction. Attempts to supershift API1-bound Jun with ER in electrophoretic mobility shift assays or to coimmunoprecipitate a Jun-ER complex, did not detect direct interactions (data not shown). It is possible that these interactions are not strong enough to withstand the experimental conditions. Alternatively, cofactors such as steroid receptor coactivator 1 or other proteins may bridge or stabilize the Jun-ER complex.

Previous studies have demonstrated a direct interaction between ER and c-Jun using glutathione S-transferase pull-down assays (16, 38). It is notable, however, that in the mammalian two-hybrid assays, the ER-Jun interaction was induced by ICI 182,780 but not by estradiol, suggesting that conformational changes may influence the protein interactions. The mechanism of estradiol-induced repression remains unknown, but may be influenced by the promoter context of the estrogen-dependent regulatory sites. For example, activation of interleukin 6 promoter requires the synergistic activity of two transcription factors, CAAT enhancer-binding protein β and NF-κB. In this case, estradiol-induced repression appears to involve interactions with each of these factors (13, 14). Another possible repression mechanism could involve estrogen-mediated inhibition of the Jun N-terminal kinase pathway (39). For example, estrogen-dependent repression of the receptor activator of NF-κB ligand appears to involve down-regulation of c-Jun expression and a decrease in Jun phosphorylation by the c-Jun N-terminal kinase (40).

As with the API1 reporter, WT ER and the DBD mutants activate Gal4-Jun dependent transcription in the presence of ICI 182,780. We found that a construct containing only the D, E, and F domains of ER does not affect transcription from the API1 reporter despite hormonal treatment, whereas the construct lacking the A/B domain but containing the DBD alters transcription in the same manner as WT ER (data not shown). These findings are consistent with several published reports (16, 18, 38) and raise the possibility that ER interactions with Jun involve a region within the DBD. It is also notable that the K210A mutation eliminates activity through the nonclassical pathway, as well as interaction with Jun, even though this mutant retains partial activity through the ERE. Because neither ER zinc finger is embedded within the protein structure, the zinc fingers may participate in protein-protein interactions.

It is well established that coactivators are involved in the classical pathway. Using selective ER mutants (I362R and K366D) that alter interactions with coactivators, we found that these mutants not only affect the classical pathway but also impair ER action through the nonclassical API1 pathway. The hydrophobic pocket where these mutants were introduced interacts with both coactivators and corepressors. For example, the mutation of residues analogous to Ile-362 and Lys-366 in thyroid hormone receptor α diminishes triiodothyronine activation but also impairs basal repression and the interaction with corepressors nuclear receptor corepressor (NCoR) and silencing mediator for retinoic acid and thyroid hormone receptors (SMRT) (41). It is therefore possible that the I362R and K366D mutations affect interactions with corepressors, although we did not detect any interactions between ER and corepressors in two-hybrid assays (data not shown), perhaps because these interactions are weaker than the ER-coactivator interactions.

One can speculate that the reversal of the ligands’ effects on the nonclassical pathway is because of the reversal of cofactors bound to liganded ER. It is somewhat counterintuitive that the antagonist ICI 182,780 might cause an interaction between the ER and coactivators and that estradiol would induce an interaction between the ER and corepressors. However, it is possible that when the ER is involved in a protein-protein interaction instead of binding to an ERE, the hydrophobic cofactor binding pocket may assume a different shape, shifting the interactions of associated proteins. As mentioned above, the same region of the LBD recognizes both coactivators and corepressors (41), increasing the likelihood that subtle changes in the tertiary protein structure could change a subset of proteins recognized by the ER.

The I362R mutant provides an additional argument in support of the hypothesis that subtle changes in protein structure can have a profound effect on the recognition of coactivators. This mutation does not completely eliminate the interaction with coactivators and therefore still stimulates transcription through the classical pathway in the presence of estradiol. However, this mutant also activates transcription in the presence of an antagonist. In this respect, the I362R mutation resembles some mutations of helix 12 that "switch" an antagonist to an agonist. Examples include the mutant L540Q of human ERα (42) and the double mutants L543A/L544A and M547A/L548A of mouse estrogen receptor α (mERα) (43),
which are activated by ICI 164,384 and 4-hydroxytamoxifen.

We conclude that for the AP1 response element, ER interacts with other proteins instead of, or in addition to, DNA to exert its transcriptional effects. The nonclassical pathway retains the requirement for cofactors. However, the patterns of cofactor binding change, as demonstrated by the reversal of estradiol/ICI activities through the AP1 reporter. These data confirm the binding change, as demonstrated by the reversal of estradiol/ICI activities through the AP1 reporter. These data confirm the sensitivity of ER activity to subtle changes in its structure, whether caused by artificial mutations or by an altered set of associated proteins.

Acknowledgments—We thank Malcolm Parker for providing mERα cDNA, Alan Wakeling for providing ICI 182,780, and Craig Jordan for providing advice and the human P2 and human oxytocin ERE

cDNA, Alan Wakeling for providing ICI 182,780, and Craig Jordan for providing advice and the human p52 and human oxytocin ERE luciferase reporter constructs.

REFERENCES

1. Tsai, M. J., and O'Malley, B. W. (1994) Annu. Rev. Biochem. 63, 451–486
2. Ribeiro, R. C., Kushner, P. J., and Baxter, J. D. (1995) Annu. Rev. Med. 46, 443–453
3. Kumar, V., and Champon, P. (1988) Cell 55, 145–156
4. Tremblay, G. B., Tremblay, A., Labrie, F., and Giguere, V. (1999) Mol. Cell. Biol. 19, 1919–1927
5. Ogawa, S., Iino, S., Watanabe, T., Hiroi, H., Orimo, A., Hosoi, T., Ouchi, Y., and Muramatsu, M. (1998) Biochem. Biophys. Res. Commun. 243, 123–128
6. Pace, P., Taylor, J., Suntharalingam, S., Coombes, R. C., and Ali, S. (1997) J. Biol. Chem. 272, 25832–25838
7. Cowley, S. M., Hoare, S., Mosselman, S., and Parker, M. G. (1997) J. Biol. Chem. 272, 19838–19862
8. McKenna, N. J., Lanza, R. B., and O'Malley, B. W. (1999) Endocr. Rev. 20, 321–344
9. Brazowski, A. M., Pike, A. C., Dauber, Z., Hubbard, R. E., Bonn, T., Engstrom, O., Ohman, L., Greene, G. L., Gustafsson, J. A., and Carliquist, M. (1997) Nature 389, 753–758
10. Shiao, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., and Greene, G. L. (1998) Cell 95, 927–937
11. Smith, C. L., Nawaz, Z., and O'Malley, B. W. (1997) Mol. Endocrinol. 11, 657–666
12. Lavinsky, R. M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T. M., Schiff, R., Del-Rio, A. L., Ricote, M., Ngo, S., Gemsch, J., Hilsenbeck, S. G., Osborne, C. K., Glass, C. K., Rosenfeld, M. G., and Rose, D. W. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 2920–2925
13. Stein, B., and Yang, M. X. (1995) Mol. Cell. Biol. 15, 4971–4979
14. Ray, P., Ghosh, S. K., Zhang, D. H., and Ray, A. (1997) FEBS Lett. 409, 79–85
15. Paeh, K., Webb, P., Kuiper, G. G., Nilsson, S., Gustafsson, J., Kushner, P. J., and Scanlan, T. S. (1997) Science 277, 1508–1510
16. Webb, P., Lopez, G. N., Uhl, R. M., and Kushner, P. J. (1995) Mol. Endocrinol. 9, 443–456
17. Webb, P., Nguyen, P., Valentine, C., Lopez, G. N., Kwok, G. R., McInerney, E., Katzenellenbogen, B. S., Enmark, E., Gustafsson, J. A., Nilsson, S., and Kushner, P. J. (1999) Mol. Endocrinol. 13, 1672–1685
18. Umayathya, Y., Kawamoto, R., Watada, H., Imano, E., Iwama, N., Morishima, T., Yanamaki, Y., Kajimoto, Y., and Kamada, T. (1994) J. Biol. Chem. 269, 16433–16442
19. Gauth, M. P., Bellard, M., Scheuer, l., Champon, P., and Sassone-Corsi, P. (1990) Cell 63, 1267–1276
20. Miller, C. D., and Miller, W. L. (1996) Endocrinology 137, 3437–3446
21. Schmitt, M., Bauso, P., Simon, P., Quasche, D., Geoffroy, V., Marschel, C., Kempp, J., and Quirin-Stricker, C. (1985) J. Neurosci. Res. 40, 152–164
22. Sadowski, I., and Paddin, M. (1989) Nucleic Acids Res. 17, 7539
23. Gehm, B. D., McAndrews, J. M., Chien, P. Y., and Jameson, J. L. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 14138–14143
24. Angel, P., Imagawa, M., Chiu, R., Stein, B., Imbra, R. J., Rahmsdorf, H. J., Jonat, C., Herrlich, P., and Karin, M. (1987) Cell 49, 729–739
25. Tagami, T., Lutz, W. H., Kumar, R., and Jameson, J. L. (1998) Biochem. Biophys. Res. Commun. 253, 358–363
26. Margoleske, R. F., McHendry-Rinde, B., and Horn, R. (1993) BioTechniques 15, 906–911
27. Naguya, T., Madison, L. D., and Jameson, J. L. (1992) J. Biol. Chem. 267, 13014–13019
28. Chien, P. Y., Ito, M., Park, Y., Tagami, T., Gehm, B. D., and Jameson, J. L. (1999) Mol. Endocrinol. 13, 2122–2136
29. Johnson, W., Albanese, C., Handeweger, S., Williams, T., Pestell, R. G., and Jameson, J. L. (1997) J. Biol. Chem. 272, 15405–15412
30. Kumar, V., Green, S., Stack, G., Berry, M., Jin, J. R., and Champon, P. (1987) Cell 51, 941–951
31. Mader, S., Kumar, V., de Verneuil, H., and Champon, P. (1989) Nature 338, 271–274
32. Schwabe, J. W., Chapman, L., Finch, J. T., and Rhodes, D. (1993) Cell 75, 567–578
33. Henttu, P. M., Kalkhooven, E., and Parker, M. G. (1997) Mol. Cell. Biol. 17, 1832–1839
34. Mak, H. Y., Hoare, S., Henttu, P. M., and Parker, M. G. (1999) Mol. Cell. Biol. 19, 3895–3903
35. Srivastava, S., Weitzmann, M. N., Cenci, S., Ross, F. P., Adler, S., and Pacifici, R. (1999) J. Clin. Invest. 104, 503–513
36. Montano, M. M., and Katzenellenbogen, B. S. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2581–2586
37. Homma, H., Kurachi, H., Nisio, Y., Takeda, T., Yamamoto, T., Adachi, K., Morishige, K., Ohmichi, M., Matsuzawa, Y., and Murata, Y. (2000) J. Biol. Chem. 275, 11404–11411
38. Sabbah, M., Courilleau, D., Mester, J., and Reudeubil, G. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 11217–11222
39. Caesler, C., Gonzalez-Sanchez, J. M., and Munoz, A. (1997) Genes Dev. 11, 3351–3364
40. Shevde, N. K., Bendixen, A. C., Dienger, K. M., and Pike, J. W. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 7829–7834
41. Hu, X., and Lazar, M. A. (1998) Nature 402, 93–96
42. Montano, M. M., Ekema, K., Krueger, R. D., Keller, A. L., and Katzenellenbogen, B. S. (1996) Mol. Endocrinol. 10, 230–242
43. Mahfoudi, A., Roulet, E., Davoine, S., Parker, M. G., and Wahl, W. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 4206–4210

Nonclassical Pathway of Estrogen Receptor Action

13621